1312786-80-3 Usage
Description
(E)-tert-butyl 2-(hydroxyimino)-3-oxobutanoate, with the molecular formula C9H17NO3, is a chemical compound derived from the amino acid proline. It is a versatile building block in organic synthesis and is widely recognized for its role in the synthesis of beta-lactam antibiotics, which are crucial in treating bacterial infections. (E)-tert-butyl 2-(hydroxyiMino)-3-oxobutanoate also holds potential in the development of new drugs for conditions such as cancer and neurological disorders, making it a valuable tool in medicinal chemistry research.
Uses
Used in Pharmaceutical Synthesis:
(E)-tert-butyl 2-(hydroxyimino)-3-oxobutanoate is used as a precursor in the synthesis of various pharmaceuticals and organic compounds. Its role in creating new and improved drugs is significant, particularly in the development of beta-lactam antibiotics that are essential for combating bacterial infections.
Used in Antibacterial Applications:
In the medical industry, (E)-tert-butyl 2-(hydroxyimino)-3-oxobutanoate is used as a key component in the production of beta-lactam antibiotics. These antibiotics are vital for treating a wide range of bacterial infections, making this compound an essential part of the pharmaceutical development process.
Used in Cancer and Neurological Disorder Research:
(E)-tert-butyl 2-(hydroxyimino)-3-oxobutanoate is also used as a starting material in the research and development of new drugs for cancer and neurological disorders. Its potential in this area highlights the compound's versatility and importance in advancing medical treatments.
Used in Medicinal Chemistry Research:
As a valuable tool in medicinal chemistry, (E)-tert-butyl 2-(hydroxyimino)-3-oxobutanoate is used in the exploration of new drug candidates and the enhancement of existing pharmaceuticals. Its role in this field is crucial for the ongoing development of innovative and effective treatments for various health conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 1312786-80-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,1,2,7,8 and 6 respectively; the second part has 2 digits, 8 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1312786-80:
(9*1)+(8*3)+(7*1)+(6*2)+(5*7)+(4*8)+(3*6)+(2*8)+(1*0)=153
153 % 10 = 3
So 1312786-80-3 is a valid CAS Registry Number.
1312786-80-3Relevant articles and documents
Development of a novel conjugatable sunitinib analogue validated through in vitro and in vivo preclinical settings
El Mubarak, Mohamed A.,Leontari, Iliana,Efstathia, Giannopoulou,Vrettos, Eirinaios I.,Shaikh, Abdul kadar,Konstantinos, Siatis E.,Danika, Charikleia,Kalofonos, Haralabos P.,Tzakos, Andreas G.,Sivolapenko, Gregory B.
, p. 515 - 523 (2018)
Sunitinib is an oral FDA/EMEA approved multi-targeted tyrosine kinase inhibitor. It possesses anti-angiogenic and antitumor activity against a variety of advanced solid tumors. However, its chemical core does not allow a potential linkage to tumor-homing elements that could eventually enhance its potency. Therefore, a novel linkable sunitinib derivative, designated SB1, was rationally designed and synthesized. The pharmaceutical profile of SB1 was explored both in vitro and in vivo. Mass spectrometry and NMR spectroscopy were utilized for characterization, while MTT assays and LC-MS/MS validated protocols were used to explore its antiproliferative effect and stability, respectively. Cytotoxicity evaluation in three glioma cells showed that SB1 preserved the antiproliferative effect of sunitinib. SB1 was stable in vitro after 24 h incubation in mouse plasma, while both agents exhibited bioequivalent pharmacokinetic characteristics after i.v. administration in Balb/c mice. To evaluate the levels of SB1 in mouse plasma, a novel analytical method was developed and validated in accordance to the US FDA and the EU EMA guidelines. We formulated a novel linkable sunitinib analog exhibiting similar antiproliferative and apoptotic properties with native sunitinib in glioma cell lines. Both SB1 and native sunitinib showed identical in vitro stability in mouse plasma and pharmacokinetics after i.v. administration in Balb/c mice.
